Patient characteristics | Anti-PD1 + Cetirizine (n = 71) n (%) | Anti-PD1 alone n = 50, n (%) |
---|---|---|
Age (years), mean (range) | 61 (27–90) | 64 (38–91) |
Gender (female/male) | 30 (42.3)/41 (57.7) | 23 (43.8)/27 (56.2) |
Melanoma AJCC VII stage | Â | Â |
• Stage IV | 67 (94.4) | 47 (94.0) |
• Stage IIIC | 3 (4.2) | 2 (4.0) |
• Stage IIIB | 1 (1.4) | 1 (2.0) |
CNS metastases at baseline | 14 (19.7) | 14 (28.0) |
BRAF status | Â | Â |
• Wild-type | 56 (78.9) | 35 (70.0) |
• Mutation | 10 (14.1) | 12 (24.0) |
• NA | 5 (7.0) | 3 (6.0) |
Type of anti-PD-1 agent | Â | Â |
• Pembrolizumab | 25 (35.2) | 18 (36.0) |
• Nivolumab | 46 (64.8) | 32 (64.0) |
Line of treatment (anti-PD-1) | Â | Â |
• First-line treatment | 49 (69.0) | 39 (78.0) |
• Second-line treatment | 22 (31.0) | 11 (22.0) |
Type of previous therapy | Â | Â |
• Ipilimumab | 22 (100) | 11 (100) |
Response rate at first assessment | Â | Â |
• Complete response | 8 (11.3) | 3 (6.0) |
• Partial response | 16 (22.5) | 8 (16.0) |
• Stable disease | 24 (33.8) | 9 (18.0) |
• Progression disease | 23 (32.4) | 30 (60.0) |
ECOG PS | Â | Â |
• 0/1 | 63 (88.7) | 40 (80.0) |
• > 2 | 8 (11.3) | 10 (20.0) |
Allergic patients | 4 (5.7) | 5 (10.0) |
Drugs related allergies | 3 (4.2) | 4 (8.0) |
Sseasonal allergies | 1 (1.4) | 1 (2.0) |
Median OS (months) | 27.59 | 19.30 |
Median PFS (months) | 18.05 | 10.02 |
M category | Â | Â |
• M0 | 4 (5.6) | 2 (4.0) |
• M1a | 9 (12.7) | 7 (14) |
• M1b | 9 (12.7) | 7 (14.0) |
• M1c | 49 (69.0) | 34 (68.0) |
LDH | Â | Â |
• High | 22 (31.0) | 17 (34.0) |
• Normal | 25 (35.2) | 23 (46) |
• NA | 24 (33.8) | 10 (20) |